TheraRadar
Data updated: May 26, 2026

IMIPENEM AND CILASTATIN (cilastatin sodium)

Infectious Disease Approved 2011-11-16
3
Indications
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-11-16
Routes
INTRAVENOUS
Dosage Forms
POWDER

IMIPENEM AND CILASTATIN Approval History

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
31 FDA actions from 2011 to 2024
Apr 2024 SUPPL
Label · Labeling
Feb 2024 SUPPL
Label · Labeling
Dec 2019 ORIGINAL
Update

What IMIPENEM AND CILASTATIN Treats

3 FDA approvals

Originally approved for its first indication in 2011 . Covers 3 distinct patient populations.

  • Other (3)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT06886464 PONTiAK NEPH24-1191 Ph 2 recruiting Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IMIPENEM AND CILASTATIN FDA Label Details

Track IMIPENEM AND CILASTATIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.